Catalent and Australian biomarker firm teams on prostate cancer ADC

Catalent and Australian biomarker firm teams on prostate cancer ADC

Minomic International has teamed up with Catalent to develop an antibody-drug conjugate (ADC) to target prostate cancer.

Minomic ia an Australian biomarker discovery company specialising in in-vitro-diagnostics, diagnostic imaging and therapeutics for prostate cancer, and under the agreement Catalent will produce the antibody for a clinical study using its GPEx technology platform.

“GPEx technology offers many advantages compared to conventional cell line engineering systems, including increased flexibility and higher, more stable yields,” said President of Advanced Delivery Technologies for Catalent, Barry Littlejohns.

“Early signs in the study are extremely encouraging,” Brad Walsh, CEO of Minomic, added. “We are pleased to be working with Catalent on this exciting project as Catalent’s flexibility on smaller cGMP batch production allows material supply quickly and efficiently.”

The deal, of which financial details were not made public, also includes scope for larger scale manufacturing - depending on the success of initial clinical studies – from Catalent’s biomanufacturing site in Madison, Wisconsin, which opened its doors last year after being purchased from GE Healthcare in 2011.

Like other contract development and manufacturing organisations (CDMOs) – Fujifilm, Piramal, Lonza and Carbogen Amcis - Catalent has been investing in its ADC capabilities and technologies. In April 2013, Catalent acquired the license to Redwood Bioscience’s SMARTag ADC conjugation technology, and earlier this year told this publication it was upping its stake in the Californian biotech.

Related News

Catalent calls  for closer collaboration

Catalent calls for greater academic and industry collaboration on delivery tech

Catalent to tap particle size engineering industry with Micron buy

Catalent to tap particle size engineering industry with Micron buy

Catalent Contract

Catalent contracted to manufacture Valerion's orphan drug candidates

Catalent will market its cell lines to Asia.

Catalent and Mitsubishi GC team up for Asian cell line offering

Catalent has added a second line for packaging pre-filled syringes. (Image Nicola Sapiens)

Catalent expands EU storage and packaging sites

Catalent to use GPEx tech to make Amarantus' protein candidate

Catalent to use GPEx cell line tech to make Amarantus' protein candidate

US FDA to review new drug application using Catalent softgel drug delivery tech

US FDA to review new drug application using Catalent softgel drug delivery tech

Catalent's biologics business grew in FY 2015, despite the firm's overall stagnant sales

Catalent to continue "disproportionate" focus on biologics through M&A and tech deals

Catalent set to expand single-use biologics facility in Wisconsin

Catalent to expand biologics facility to keep up with capacity demand

Image: iStock/BamBamImages

Roche and Catalent team up in $600m conjugation tech deal

Management is looking to increase capacity at Catalent's biologics facility in Madison, Wisconsin

Technology, not capacity, driving Catalent’s biologics strategy

Catalent commits to ADCs by upping its stake in Redwood

Catalent commits to ADCs by upping its stake in Redwood

Catalent enters ADC market

Catalent Gets ADC Tech and Enters Fast-Growing Niche Market

Catalent Quadruples Biologics Services with Opening of New plant

Catalent Quadruples Biologics Services with Opening of New plant

Talking ADCs with SAFC, Piramal and Catalent at CPhI Frankfurt

'The sexiness of the ADC world' - CMOs talk antibody-drug hybrids at CPhI

New unit brings Catalent's services together

Catalent Combines Core Drug Delivery Services Into New Unit

Cytotoxics to lead CMO growth, says F&S report

CMOs to Strengthen on Biopharma's Cytotoxic Demand, Report says

ADCs a big opportunity for Big Pharma say experts

Big Pharma business opportunities driving ADC boom say experts

Related Products

See more related products